Chen, Y., You, F., Jiang, L., Li, J., Zhu, X., Bao, Y., . . . Yang, L. (2017). Gene-modified NK-92MI cells expressing a chimeric CD16-BB-ζ or CD64-BB-ζ receptor exhibit enhanced cancer-killing ability in combination with therapeutic antibody. Oncotarget.
Dyfyniad Arddull ChicagoChen, Ying, et al. "Gene-modified NK-92MI Cells Expressing a Chimeric CD16-BB-ζ or CD64-BB-ζ Receptor Exhibit Enhanced Cancer-killing Ability in Combination With Therapeutic Antibody." Oncotarget 2017.
Dyfyniad MLAChen, Ying, et al. "Gene-modified NK-92MI Cells Expressing a Chimeric CD16-BB-ζ or CD64-BB-ζ Receptor Exhibit Enhanced Cancer-killing Ability in Combination With Therapeutic Antibody." Oncotarget 2017.
Rhybudd: Mae'n bosib nad yw'r dyfyniadau hyn bob amser yn 100% cywir.